Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition

Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. Our retrospective study assessed liquid biopsies and tumor tissue analyses for two p...

Full description

Saved in:
Bibliographic Details
Main Authors: Melzer, Yasmin F. (Author) , Fergen, Nadine L (Author) , Mess, Christian (Author) , Stadler, Julia-Christina (Author) , Geidel, Glenn (Author) , Schwietzer, Ysabel A (Author) , Kött, Julian (Author) , Pantel, Klaus (Author) , Schneider, Stefan W (Author) , Utikal, Jochen (Author) , Wladykowski, Ewa (Author) , Vidal-y-Sy, Sabine (Author) , Bauer, Alexander (Author) , Gebhardt, Christoffer (Author)
Format: Article (Journal)
Language:English
Published: February 2025
In: Translational oncology
Year: 2025, Volume: 52, Pages: 1-9
ISSN:1936-5233
DOI:10.1016/j.tranon.2024.102224
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.tranon.2024.102224
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1936523324003504
Get full text
Author Notes:Yasmin F Melzer, Nadine L Fergen, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Ysabel A Schwietzer, Julian Kött, Klaus Pantel, Stefan W Schneider, Jochen Utikal, Ewa Wladykowski, Sabine Vidal-y-Sy, Alexander T Bauer, Christoffer Gebhardt

MARC

LEADER 00000caa a2200000 c 4500
001 1923871889
003 DE-627
005 20250717012143.0
007 cr uuu---uuuuu
008 250429s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.tranon.2024.102224  |2 doi 
035 |a (DE-627)1923871889 
035 |a (DE-599)KXP1923871889 
035 |a (OCoLC)1528045063 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Melzer, Yasmin F.  |e VerfasserIn  |0 (DE-588)1364062267  |0 (DE-627)1923872745  |4 aut 
245 1 0 |a Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition  |c Yasmin F Melzer, Nadine L Fergen, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Ysabel A Schwietzer, Julian Kött, Klaus Pantel, Stefan W Schneider, Jochen Utikal, Ewa Wladykowski, Sabine Vidal-y-Sy, Alexander T Bauer, Christoffer Gebhardt 
264 1 |c February 2025 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.04.2025 
520 |a Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. Our retrospective study assessed liquid biopsies and tumor tissue analyses for two potential biomarkers: danger-associated molecular pattern (DAMP) S100A8/A9 and its source, neutrophils. In 43 metastatic unresected stage III/IV melanoma patients, elevated serum levels of S100A8/A9 and neutrophils before and during ICI treatment correlated with worse outcomes. Furthermore, in 113 melanoma patients, neutrophil expression in the tumor microenvironment (TME) was associated with relapse and reduced survival. Measuring S100A8/A9 and neutrophils could enhance immunotherapy monitoring by predicting impaired clinical outcomes and non-response to ICIs. Serum S100A8/A9 levels and neutrophil counts at baseline (T0) and during treatment (T3) correlated with reduced progression-free survival (PFS). Elevated S100A8/A9 levels at T0 and T3 negatively impacted overall survival (OS). Notably, neutrophil infiltration was more prevalent in primary melanomas than in nevi and metastases, and its presence in primary melanomas was linked to poorer survival. S100A8/A9 serum levels, neutrophil counts, and tumor-associated neutrophil infiltration represent promising biomarkers for predicting treatment response and clinical outcomes in melanoma patients receiving ICIs. - Significance - These findings underscore the critical need for reliable biomarkers in melanoma research, particularly for predicting responses to immune-checkpoint inhibitors (ICIs). Identifying S100A8/A9 levels and neutrophil infiltration as potential indicators of treatment outcomes offers valuable insights for personalized therapy decisions. By enhancing monitoring and prognosis assessment, these biomarkers contribute to refining treatment strategies, ultimately improving patient care and outcomes. This research bridges gaps in understanding melanoma response mechanisms and highlights avenues for further investigation into immune-related markers, fostering advancements in precision medicine for melanoma patients. 
650 4 |a Biomarker 
650 4 |a Immune-checkpoint inhibitors 
650 4 |a Inflammation 
650 4 |a Melanoma 
650 4 |a Neutrophils 
650 4 |a S100A8/A9 
650 4 |a Tumor progression 
700 1 |a Fergen, Nadine L  |e VerfasserIn  |4 aut 
700 1 |a Mess, Christian  |e VerfasserIn  |4 aut 
700 1 |a Stadler, Julia-Christina  |e VerfasserIn  |4 aut 
700 1 |a Geidel, Glenn  |e VerfasserIn  |4 aut 
700 1 |a Schwietzer, Ysabel A  |e VerfasserIn  |4 aut 
700 1 |a Kött, Julian  |e VerfasserIn  |4 aut 
700 1 |a Pantel, Klaus  |e VerfasserIn  |4 aut 
700 1 |a Schneider, Stefan W  |e VerfasserIn  |4 aut 
700 1 |a Utikal, Jochen  |d 1974-  |e VerfasserIn  |0 (DE-588)1026463750  |0 (DE-627)726765015  |0 (DE-576)371816580  |4 aut 
700 1 |a Wladykowski, Ewa  |e VerfasserIn  |4 aut 
700 1 |a Vidal-y-Sy, Sabine  |e VerfasserIn  |4 aut 
700 1 |a Bauer, Alexander  |d 1978-  |e VerfasserIn  |0 (DE-588)143496425  |0 (DE-627)646577778  |0 (DE-576)337385572  |4 aut 
700 1 |a Gebhardt, Christoffer  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Translational oncology  |d Ann Arbor, Mich. : [Verlag nicht ermittelbar], 2008  |g 52(2025) vom: Feb., Artikel-ID 102224, Seite 1-9  |h Online-Ressource  |w (DE-627)57436482X  |w (DE-600)2443840-6  |w (DE-576)28492945X  |x 1936-5233  |7 nnas  |a Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition 
773 1 8 |g volume:52  |g year:2025  |g month:02  |g elocationid:102224  |g pages:1-9  |g extent:9  |a Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition 
856 4 0 |u https://doi.org/10.1016/j.tranon.2024.102224  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S1936523324003504  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250429 
993 |a Article 
994 |a 2025 
998 |g 1026463750  |a Utikal, Jochen  |m 1026463750:Utikal, Jochen  |d 60000  |e 60000PU1026463750  |k 0/60000/  |p 10 
999 |a KXP-PPN1923871889  |e 4715609940 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"February 2025","dateIssuedKey":"2025"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"note":["Gesehen am 23.06.2025"],"disp":"Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibitionTranslational oncology","title":[{"title":"Translational oncology","title_sort":"Translational oncology"}],"recId":"57436482X","id":{"issn":["1936-5233"],"eki":["57436482X"],"zdb":["2443840-6"]},"pubHistory":["1.2008 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"Ann Arbor, Mich.","dateIssuedKey":"2008","publisher":"[Verlag nicht ermittelbar]","dateIssuedDisp":"2008-"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"1-9","year":"2025","extent":"9","volume":"52","text":"52(2025) vom: Feb., Artikel-ID 102224, Seite 1-9"},"language":["eng"]}],"recId":"1923871889","person":[{"family":"Melzer","role":"aut","display":"Melzer, Yasmin F.","roleDisplay":"VerfasserIn","given":"Yasmin F."},{"given":"Nadine L","roleDisplay":"VerfasserIn","display":"Fergen, Nadine L","family":"Fergen","role":"aut"},{"role":"aut","family":"Mess","given":"Christian","display":"Mess, Christian","roleDisplay":"VerfasserIn"},{"display":"Stadler, Julia-Christina","roleDisplay":"VerfasserIn","given":"Julia-Christina","family":"Stadler","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Geidel, Glenn","given":"Glenn","role":"aut","family":"Geidel"},{"family":"Schwietzer","role":"aut","display":"Schwietzer, Ysabel A","roleDisplay":"VerfasserIn","given":"Ysabel A"},{"display":"Kött, Julian","roleDisplay":"VerfasserIn","given":"Julian","family":"Kött","role":"aut"},{"given":"Klaus","roleDisplay":"VerfasserIn","display":"Pantel, Klaus","role":"aut","family":"Pantel"},{"display":"Schneider, Stefan W","roleDisplay":"VerfasserIn","given":"Stefan W","family":"Schneider","role":"aut"},{"family":"Utikal","role":"aut","given":"Jochen","display":"Utikal, Jochen","roleDisplay":"VerfasserIn"},{"role":"aut","family":"Wladykowski","roleDisplay":"VerfasserIn","display":"Wladykowski, Ewa","given":"Ewa"},{"given":"Sabine","display":"Vidal-y-Sy, Sabine","roleDisplay":"VerfasserIn","family":"Vidal-y-Sy","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Bauer, Alexander","given":"Alexander","role":"aut","family":"Bauer"},{"family":"Gebhardt","role":"aut","given":"Christoffer","display":"Gebhardt, Christoffer","roleDisplay":"VerfasserIn"}],"id":{"doi":["10.1016/j.tranon.2024.102224"],"eki":["1923871889"]},"note":["Gesehen am 29.04.2025"],"name":{"displayForm":["Yasmin F Melzer, Nadine L Fergen, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Ysabel A Schwietzer, Julian Kött, Klaus Pantel, Stefan W Schneider, Jochen Utikal, Ewa Wladykowski, Sabine Vidal-y-Sy, Alexander T Bauer, Christoffer Gebhardt"]},"title":[{"title_sort":"Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition","title":"Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition"}]} 
SRT |a MELZERYASMEVALUATION2025